Buy Alert: 10 Stocks Analysts Upgraded on Wednesday

8. Republic Services (NYSE:RSG)

Market Cap: $75.96 billion

Average Upside Potential: 4%

Number of Hedge Fund Holders: 58

JPMorgan analyst Tami Zakaria upgraded Republic Services from Neutral to Overweight on November 11 and raised her December 2027 price target to $295. Her argument is that solid waste volume growth should turn positive in 2027 after three years of declines.

The third-quarter report supports the shift. Adjusted earnings came in at $1.94 per share, and small and large container volumes each gained 50 basis points, the first time in more than three years that both rose together. Management raised full-year guidance on the back of it. The board also authorized a larger share repurchase program, and the company keeps adding businesses through acquisitions. Its Environmental Solutions unit, which handles hazardous and PFAS-related waste, grew revenue sharply. Recycled commodity prices per ton also ran well above the prior year.

Republic collects and recycles commercial, industrial and residential waste and runs landfills across the US. It has also set a target of $100 million in added earnings from AI pricing tools by 2028. Republic Services (RSG) Is Winning On Price While Volumes Slip traced the volume problem this upgrade bets is ending.

7. Gladstone Investment (NASDAQ:GAIN)

Market Cap: $604.90 million

Average Upside Potential: 11%

Number of Hedge Fund Holders: 4

Ladenburg Thalmann analyst Christopher Nolan upgraded Gladstone Investment from Neutral to Buy on November 11 with a $17 price target. The call follows the lender’s fiscal second-quarter report, where attention fell on the exit of SFEG, a portfolio company sold after the quarter ended. Management said the proceeds are expected in the third or fourth quarter of the fiscal year, after SFEG sold its operating subsidiary to Enerpac Tool Group.

Gladstone Investment is a business development company that lends to, and buys stakes in, lower middle market businesses. Its SFEG equity stake is expected to produce the largest capital gain in the company’s history and could fund supplemental distributions. Net asset value rose to $16.43 per share, while adjusted net investment income of $0.18 per share fell short of the consensus estimate.

The monthly payout is backed by spillover income that covers about six months of distributions. Management also pointed to a new McFarlane Toys investment and said the portfolio has no software exposure. Monthly payers like this one are the subject of 10 Best Dividend Stocks with Monthly Payout, one of our recent lists.

6. BILL Holdings (NYSE:BILL)

Market Cap: $4.64 billion

Average Upside Potential: 12%

Number of Hedge Fund Holders: 48

UBS started coverage of BILL Holdings with a Buy rating and a $64 price target on November 11. The firm calls it the rare public pure play on business-to-business payments and expects low double-digit to mid-teens core revenue growth, with earnings compounding faster than revenue. It credits an improving go-to-market motion, a better customer mix, deeper monetization and operating leverage, and says continued share buybacks add to the case.

BILL sells software that helps small and midsize businesses handle payables, receivables and spend, and it runs a payments network of suppliers and buyers around its customers. The latest quarter supports the efficiency story: core revenue grew 14% and non-GAAP operating margin reached 39%. Headline revenue missed estimates only because an accounting change now nets card rewards against revenue. Management raised its full-year earnings outlook and repurchased about $305 million of stock.

Investors are weighing that profit push against slowing card growth and a sales restructuring management still describes as unfinished. We looked at why earnings are outpacing revenue in BILL (BILL) Is Growing Earnings Faster Than Revenue. What Is Driving the Gap?

5. Liquidia (NASDAQ:LQDA)

Market Cap: $4.94 billion

Average Upside Potential: 15%

Number of Hedge Fund Holders: 44

Raymond James analyst Ryan Deschner upgraded Liquidia from Outperform to Strong Buy on November 11 and raised his price target to $77. He cited the continued strength of the Yutrepia launch, with accelerating shipments, strong referral-to-start conversion and a growing prescriber base, with the share of monthly referrals that become patient starts staying high. October shipments were the highest since launch, and he considers the legal overhang removed after the settlement.

Liquidia makes Yutrepia, an inhaled dry-powder treprostinil for pulmonary arterial hypertension. Third-quarter net product sales reached $222.7 million, up 31% from the prior quarter, though a $389.7 million settlement charge with United Therapeutics pushed GAAP results to a loss. The settlement also removed PH-ILD from the label, and the company expects to fund the payments from Yutrepia sales and cash on hand.

Deschner expects some volatility over the next few quarters as the launch settles under a PAH-only label. He raised his estimates for Yutrepia and the L606 candidate, and Needham lifted its target the same day. Biotech names favored by large investors are the focus of 10 Best Biotech Stocks to Invest In According to Billionaires.